Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215451 | 0.81 | MEN1 (0.44) | LMNAMAPTMAPK1IDO1CYP1A2 | |
| SCHEMBL6608440 | 0.78 | MAPK1 (0.41) | MAPK1ARNPC1RAB9AGSK3B | |
| SCHEMBL6177597 | 0.78 | METAP2 (0.41) | LMNAMAPTCYP3A4NPC1RAB9A | |
| SCHEMBL6609394 | 0.78 | PDGFRB (0.41) | LMNAMAPTIDO1NPC1RAB9A | |
| SCHEMBL27717280 | 0.77 | MAPK1 (0.49) | MAPK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6165643 | 0.76 | KMT2A (0.41) | LMNAMAPTCYP3A4NPC1RAB9A | |
| SCHEMBL11101854 | 0.76 | DYRK1A (0.43) | MAPTGSK3BKDM4EKMT2ADYRK1A | |
| Hydrochloric Acid SCHEMBL27695082 | 0.76 | MAPK1 (0.48) | MAPK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25214532 | 0.75 | MAPT (0.42) | LMNAMAPTMAPK1IDO1AR | |
| SCHEMBL14511620 | 0.75 | GSK3B (0.53) | LMNAMAPTMAPK1IDO1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1581222-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004060362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0507650-B1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1996-05-22 | — | — | EP | disclosed |
| US-5280030-A | Containing 1-benz(oxazole, thiazole or imidazole)-4-imidazole piperidine compound | SYNTHELABO (FR) | 1994-01-18 | — | — | US | disclosed |
| EP-0507650-A1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | LMNA 3889/4885MAPT 3726/4885MAPK1 160/4885 |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | LMNA 90/4885MAPT 3300/4885MAPK1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.